New ADC Approaches Aim to Broaden Target Coverage.

Preliminary efficacy data suggest that B7-H3-targeting elfetabart drozuntecan plus the PD-L1–VEGF-A bispecific pumitamig could be a potential combination strategy in solid tumors.

• Why it matters: The ADC field is increasingly seeking ways to target more than one tumor antigen at a time, addressing limitations of single-target approaches.
• What they did: The work reviews emerging multi-target ADC strategies, including a combination of elfetabart drozuntecan with pumitamig and two bispecific ADCs targeting EGFR–c-MET and EGFR–B7-H3.
• The result: The combination is linked to preliminary efficacy signals, and the EGFR–c-MET and EGFR–B7-H3 bispecific ADCs appear active across multiple solid tumor types.